Gout and Metabolic Syndrome: a Tangled Web.
Level 5 - mechanism / opinion, no new human data
Narrative mechanistic and epidemiological review without systematic review methodology.
PubMed 28844079 · doi:10.1007/s11926-017-0688-y
What was done
This narrative review synthesized physiological, epidemiological, and mechanistic evidence from human and animal studies exploring the links between gout, hyperuricemia, and components of the metabolic syndrome (including type 2 diabetes, hypertension, hyperlipidemia, cardiovascular disease, renal disease, and obesity).
What was found
The abstract reports no quantitative values or statistical metrics. It describes qualitative findings indicating that hyperuricemia promotes inflammation, adipogenesis, lipogenesis, glucose/insulin dysregulation, liver disease, and cardiovascular pathology. Additionally, fructose intake was noted to stimulate urate biosynthesis, and a proposed fructose/urate metabolic loop inhibits AMP kinase (AMPK) through regulators like AMP deaminase and fructokinase. Preliminary evidence indicates that inhibiting intracellular urate synthesis may restore AMPK activity.
Why it matters
Understanding gout as both an inflammatory and metabolic disorder suggests that urate-lowering or metabolic-targeted interventions could potentially help mitigate broader metabolic syndrome manifestations beyond joint disease.
Limits
The abstract provides no quantitative data, effect sizes, or study quality assessments. Because this is a narrative review combining animal models, mechanistic pathways, and observational human data, it cannot establish causal directionality in humans or determine whether treating hyperuricemia directly improves metabolic syndrome outcomes.
Cited by
- context Fructose metabolism converts directly into uric acid, exacerbating gout.